Talaris Therapeutics Stock

talaristx.comBioTechFounded: 1900Funding to Date: $100MM

Talaris Therapeutics is a late-clinical stage biotechnology company developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders.

Register for Details

For more details on financing and valuation for Talaris Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Suzanne Ildstad MD
Founder, Board Member & Chief Scientific Officer
Francois Nader
Chairman
Nancy Krieger MD
Chief Medical Officer
Scott Requadt JD
Chief Executive Officer & Board Member

Board Members

Francois Nader
Geoff MacKay
Mark McDade
Qiming Venture Partners
Nicholas Galakatos Ph.D
Blackstone Life Sciences
Sandip Agarwala
Longitude Capital
Scott Requadt JD
Suzanne Ildstad MD

Other companies like Talaris Therapeutics in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

The series A funding will be used to advance Talaris' proprietary, one-time, allogeneic cell therapy, FCR001, into later-stage clinical development.
Talaris Therapeutics, which develops cell therapies with potential to eliminate chronic immunosuppression for organ transplant recipients, raised $100m